This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

InterMune Announces Presentations Of New Research In IPF At ERS

BRISBANE, Calif., Aug. 27, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that an oral presentation and three poster presentations related to the company's research programs in idiopathic pulmonary fibrosis (IPF) will be presented at the Annual Congress of the European Respiratory Society (ERS) being held in Vienna, Austria, September 1-5.

(Logo: http://photos.prnewswire.com/prnh/20120827/SF62570LOGO)

New analyses of FVC change and Survival from the RECAP extension study of Esbriet ® (pirfenidone) will be delivered in an oral presentation.  Additionally, new data on the long-term clinical safety of Esbriet in IPF patients who have received treatment for up to 7.7 years will be presented as part of a scientific poster discussion. 

Dan Welch, Chairman, Chief Executive Officer and President of InterMune, said, "These data demonstrate that the safety profile of Esbriet in IPF patients treated for several years is generally consistent with the well characterized safety profile from previous clinical studies.  Importantly, Esbriet is the first and only agent to demonstrate long-term clinical safety in a prospective well-designed study in patients with IPF."

Two additional scientific posters, including an analysis of safety outcomes in IPF patients treated with Esbriet and commonly used concomitant medications and the results of analyses that confirm the threshold defining clinically significant changes in the 6-minute walk test in patients with IPF will also be presented.

The schedule of presentations regarding Esbriet and/or IPF at ERS is as follows (all times CET):

Sunday, September 2, 2012 2:50-14:40 hThematic Poster Presentation Dr. Carlo Albera:  " Safety and Tolerability of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis Receiving Commonly Used Concomitant Medications"Location: Hall A11/P718

Monday, September 3, 2012 14:45 - 16:45 hOral PresentationDr. Ulrich Costabel:  " Analysis of Lung Function and Survival in RECAP: An Open-label Extension Study of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis"Location: Oral Presentation OP2820/Hall A3

Tuesday, September 4, 2012 08:30 - 10:30 hPoster DiscussionDr. Dominique Valeyre:  " The Long-term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis: Integrated Analysis of Safety from Four Clinical Trials"Location: Hall A5/P3159

12:50 - 14:40 hPoster PresentationDr. Steve Nathan:  " 6-Minute Walk Test in Patients with Idiopathic Pulmonary Fibrosis: Confirmation of the Minimal Clinically Important Difference"Location: Hall A13/P3656

About RECAPRECAP is an open-label extension study for patients who participated in the Phase 3 program for Esbriet, known as CAPACITY.  The CAPACITY program (studies 004 and 006) was designed to evaluate the safety and efficacy of Esbriet in IPF patients with mild to moderate impairment in lung function. In the CAPACITY studies, 779 patients were randomized to treatment with Esbriet or placebo and 626 patients completed the study.  Of these, 603 (96 percent) were enrolled in RECAP. 

Long-term safety results from RECAP were initially presented at the Annual Congress of the European Respiratory Society (ERS) in September 2011.  These results demonstrated that long-term treatment with Esbriet was safe and generally well-tolerated, with a long-term safety profile similar to that observed in CAPACITY.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs